Rational drug design leading to the identification of a potent 5-HT 2C agonist lacking 5-HT 2B activity

ACS Medicinal Chemistry Letters

Volumn 2, Issue 12, 2011, Pages 929-932

  Chen, Gang ^a   Cho, Sung Jin ^a,c   Huang, Xi Ping ^b   Jensen, Niels H ^b,d   Svennebring, Andreas ^a   Sassano, Maria F ^b   Roth, Bryan L ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c SK Biopharmaceuticals Co   (South Korea)

^d THC Pharm   (Germany)

Author keywords

5 HT 2B receptor; 5 HT 2C receptor; agonist; hydrophobic interactions; Serotonin

Indexed keywords

8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; [2 (2 CYCLOPROPYLMETHOXYPHENYL)CYCLOPROPYL]METHYLAMINE; LORCASERIN; PYRAZINE DERIVATIVE; PYRAZINOISOINDOLINE; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; VABICASERIN; WAY 629;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 83455165053     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200206z     Document Type: Article

References (24)

1. Berger, M.; Gray, J. A.; Roth, B. L. The expanded biology of serotonin Annu. Rev. Med. 2009, 60, 355-66
2. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108, 1614-41 (Pubitemid 351796401)
3. Hoyer, D.; Martin, G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome Neuropharmacology 1997, 36, 419-28 (Pubitemid 27272086)
4. Kroeze, W. K.; Roth, B. L. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis Biol. Psychiatry 1998, 44, 1128-42 (Pubitemid 28547147)
5. Roth, B. L.; Willins, D. L.; Kristiansen, K.; Kroeze, W. K. 5-Hydroxytryptamine 2-family receptors (5-hydroxytryptamine 2A, 5-hydroxytryptamine 2B, 5-hydroxytryptamine 2C): where structure meets function Pharmacol. Ther. 1998, 79, 231-57 (Pubitemid 28393877)
6. Nichols, D. E. Hallucinogens Pharmacol. Ther. 2004, 101, 131-81 (Pubitemid 38167565)
7. Hutcheson, J. D.; Setola, V.; Roth, B. L.; Merryman, W. D. Serotonin receptors and heart valve disease-It was meant 2B Pharmacol. Ther. 2011, 132, 146-147
8. 2C receptor knockout mouse Physiol. Behav. 2003, 78, 641-9 (Pubitemid 36628092)
9. Delgado, P. L.; Moreno, F. A. Hallucinogens, serotonin and obsessive-compulsive disorder J. Psychoact. Drugs 1998, 30, 359-66 (Pubitemid 29046927)
10. 2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists Eur. J. Pharmacol. 1997, 325, 9-12 (Pubitemid 27190449)
11. 2C receptor in anti-obesity drug developments Mol. Interventions 2005, 5, 282-91
12. 2C) receptor agonists as potential antiobesity agents J. Med. Chem. 2006, 49, 4023-34 (Pubitemid 44036647)
13. 2C serotonin receptors Nature 1995, 374, 542-6
14. 2B receptor inverse agonist/antagonist activity Eur. J. Pharmacol. 2009, 615, 1-9
15. 2C receptor modulators: a patent survey Expert Opin. Ther. Pat. 2010, 20, 1429-55
16. 2C ligands: recent progress Prog. Med. Chem. 2008, 46, 281-390
17. 2C receptor: preclinical and clinical progression in multiple diseases Curr. Opin. Drug Discovery Dev. 2008, 11, 438-45 (Pubitemid 351950839)
18. Cho, S. J.; Jensen, N. H.; Kurome, T.; Kadari, S.; Manzano, M. L.; Malberg, J. E.; Caldarone, B.; Roth, B. L.; Kozikowski, A. P. Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action J. Med. Chem. 2009, 52, 1885-902
19. 2C-Selective Ligands for Possible Use in Schizophrenia ChemMedChem 2010, 5, 1221-5
20. 2C receptor agonists Acta Biochim. Biophys. Sin. (Shanghai) 2007, 39, 413-22 (Pubitemid 46990232)
21. Rodriques, K. E. A novel route to cyclopropyl ketones, aldehydes, and carboxylic acids Tetrahedron Lett. 1991, 32, 1275-8
22. Bertrand, M. B.; Neukom, J. D.; Wolfe, J. P. Mild Conditions for Pd-Catalyzed Carboamination of N-Protected Hex-4-enylamines and 1-, 3-, and 4-Substituted Pent-4-enylamines. Scope, Limitations, and Mechanism of Pyrrolidine Formation J. Org. Chem. 2008, 73, 8851-60
23. Jensen, N. H.; Rodriguiz, R. M.; Caron, M. G.; Wetsel, W. C.; Rothman, R. B.; Roth, B. L. N -Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapines antidepressant activity Neuropsychopharmacology 2008, 33, 2303-12
24. 2C receptor agonist WAY-163909; therapeutic potential in multiple indications CNS Drug Rev. 2006, 12, 167-77 (Pubitemid 46047786)